Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals

Kristin Mondy, Kevin Yarasheski, William G. Powderly, Michael Whyte, Sherry Claxton, Debra DeMarco, Mary Hoffmann, Pablo Tebas

Research output: Contribution to journalArticle

248 Citations (Scopus)

Abstract

The underlying mechanisms of several bone disorders in human immunodeficiency virus (HIV)-infected persons and any relation to antiretroviral therapy have yet to be defined. A longitudinal study was conducted to estimate the prevalence of osteopenia or osteoporosis in HIV-infected persons; to assess bone mineralization, metabolism, and histomorphometry over time; and to evaluate predisposing factors. A total of 128 patients enrolled the study, and 93 were observed for 72 weeks. "Classic" risk factors (low body mass index, history of weight loss, steroid use, and smoking) for low bone mineral density (BMD) and duration of HIV infection were strongly associated with osteopenia. There was a weak association between low BMD and receipt of treatment with protease inhibitors; this association disappeared after controlling for the above factors. Markers of bone turnover tended to be elevated in the whole cohort but were not associated with low BMD. BMD increased slightly during follow-up. Traditional risk factors and advanced HIV infection play a more significant pathogenic role in the development of osteopenia and osteoporosis associated with HIV infection than do treatment-associated factors.

Original languageEnglish (US)
Pages (from-to)482-490
Number of pages9
JournalClinical Infectious Diseases
Volume36
Issue number4
DOIs
StatePublished - Feb 15 2003

Fingerprint

Bone Density
HIV
Metabolic Bone Diseases
Bone and Bones
Virus Diseases
Osteoporosis
Physiologic Calcification
Bone Remodeling
Protease Inhibitors
Causality
Longitudinal Studies
Weight Loss
Body Mass Index
Therapeutics
Smoking
Steroids

ASJC Scopus subject areas

  • Immunology

Cite this

Mondy, K., Yarasheski, K., Powderly, W. G., Whyte, M., Claxton, S., DeMarco, D., ... Tebas, P. (2003). Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clinical Infectious Diseases, 36(4), 482-490. https://doi.org/10.1086/367569

Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. / Mondy, Kristin; Yarasheski, Kevin; Powderly, William G.; Whyte, Michael; Claxton, Sherry; DeMarco, Debra; Hoffmann, Mary; Tebas, Pablo.

In: Clinical Infectious Diseases, Vol. 36, No. 4, 15.02.2003, p. 482-490.

Research output: Contribution to journalArticle

Mondy, K, Yarasheski, K, Powderly, WG, Whyte, M, Claxton, S, DeMarco, D, Hoffmann, M & Tebas, P 2003, 'Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals', Clinical Infectious Diseases, vol. 36, no. 4, pp. 482-490. https://doi.org/10.1086/367569
Mondy, Kristin ; Yarasheski, Kevin ; Powderly, William G. ; Whyte, Michael ; Claxton, Sherry ; DeMarco, Debra ; Hoffmann, Mary ; Tebas, Pablo. / Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. In: Clinical Infectious Diseases. 2003 ; Vol. 36, No. 4. pp. 482-490.
@article{56f2639f5c0a48aab22a380d2c7d3558,
title = "Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals",
abstract = "The underlying mechanisms of several bone disorders in human immunodeficiency virus (HIV)-infected persons and any relation to antiretroviral therapy have yet to be defined. A longitudinal study was conducted to estimate the prevalence of osteopenia or osteoporosis in HIV-infected persons; to assess bone mineralization, metabolism, and histomorphometry over time; and to evaluate predisposing factors. A total of 128 patients enrolled the study, and 93 were observed for 72 weeks. {"}Classic{"} risk factors (low body mass index, history of weight loss, steroid use, and smoking) for low bone mineral density (BMD) and duration of HIV infection were strongly associated with osteopenia. There was a weak association between low BMD and receipt of treatment with protease inhibitors; this association disappeared after controlling for the above factors. Markers of bone turnover tended to be elevated in the whole cohort but were not associated with low BMD. BMD increased slightly during follow-up. Traditional risk factors and advanced HIV infection play a more significant pathogenic role in the development of osteopenia and osteoporosis associated with HIV infection than do treatment-associated factors.",
author = "Kristin Mondy and Kevin Yarasheski and Powderly, {William G.} and Michael Whyte and Sherry Claxton and Debra DeMarco and Mary Hoffmann and Pablo Tebas",
year = "2003",
month = "2",
day = "15",
doi = "10.1086/367569",
language = "English (US)",
volume = "36",
pages = "482--490",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals

AU - Mondy, Kristin

AU - Yarasheski, Kevin

AU - Powderly, William G.

AU - Whyte, Michael

AU - Claxton, Sherry

AU - DeMarco, Debra

AU - Hoffmann, Mary

AU - Tebas, Pablo

PY - 2003/2/15

Y1 - 2003/2/15

N2 - The underlying mechanisms of several bone disorders in human immunodeficiency virus (HIV)-infected persons and any relation to antiretroviral therapy have yet to be defined. A longitudinal study was conducted to estimate the prevalence of osteopenia or osteoporosis in HIV-infected persons; to assess bone mineralization, metabolism, and histomorphometry over time; and to evaluate predisposing factors. A total of 128 patients enrolled the study, and 93 were observed for 72 weeks. "Classic" risk factors (low body mass index, history of weight loss, steroid use, and smoking) for low bone mineral density (BMD) and duration of HIV infection were strongly associated with osteopenia. There was a weak association between low BMD and receipt of treatment with protease inhibitors; this association disappeared after controlling for the above factors. Markers of bone turnover tended to be elevated in the whole cohort but were not associated with low BMD. BMD increased slightly during follow-up. Traditional risk factors and advanced HIV infection play a more significant pathogenic role in the development of osteopenia and osteoporosis associated with HIV infection than do treatment-associated factors.

AB - The underlying mechanisms of several bone disorders in human immunodeficiency virus (HIV)-infected persons and any relation to antiretroviral therapy have yet to be defined. A longitudinal study was conducted to estimate the prevalence of osteopenia or osteoporosis in HIV-infected persons; to assess bone mineralization, metabolism, and histomorphometry over time; and to evaluate predisposing factors. A total of 128 patients enrolled the study, and 93 were observed for 72 weeks. "Classic" risk factors (low body mass index, history of weight loss, steroid use, and smoking) for low bone mineral density (BMD) and duration of HIV infection were strongly associated with osteopenia. There was a weak association between low BMD and receipt of treatment with protease inhibitors; this association disappeared after controlling for the above factors. Markers of bone turnover tended to be elevated in the whole cohort but were not associated with low BMD. BMD increased slightly during follow-up. Traditional risk factors and advanced HIV infection play a more significant pathogenic role in the development of osteopenia and osteoporosis associated with HIV infection than do treatment-associated factors.

UR - http://www.scopus.com/inward/record.url?scp=0037442930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037442930&partnerID=8YFLogxK

U2 - 10.1086/367569

DO - 10.1086/367569

M3 - Article

C2 - 12567307

AN - SCOPUS:0037442930

VL - 36

SP - 482

EP - 490

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 4

ER -